Lupin has received final approval for its Desoximetasone Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharms North’s Topicort Ointment, 0.05%. The product filing is from Lupin’s Pithampur (Indore) manufacturing facility. Topicort Ointment had US sales of $12.1 million, as per IMS MAT September 2016.
Lupin’s Desoximetasone Ointment USP, 0.05% is the AB rated generic equivalent of Taro Pharms North’s Topicort Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Lupin had earlier on December 6, 2016, received final approval for its Desoximetasone Ointment USP, 0.25% from USFDA to market a generic version of Taro Pharmaceuticals, Inc.’s Topicort Ointment, 0.25% having US sales of $14.4 million, as per IMS MAT September 2016.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: